Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Endometrial Hyperplasia × Everolimus × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 44 Carcinoma, Renal Cell 25 Neoplasm Metastasis 15 Neoplasms 13 Kidney Neoplasms 11 Neuroendocrine Tumors 10 Carcinoma, Neuroendocrine 9 Prostatic Neoplasms 7 Thyroid Neoplasms 6 Sarcoma 6 Meningioma 6 Melanoma 6 Lymphoma 6 Tuberous Sclerosis 5 Recurrence 5 Lymphoma, Mantle-Cell 5 Head and Neck Neoplasms 5 Endometrial Neoplasms 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Glioma 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Astrocytoma 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Neurofibromatosis 2 3

Interventions

Megestrol Acetate 4 Tirzepatide 2 Progestins 2 Atorvastatin 2 exemestane 1 estradiol, norethindrone drug combination 1 Rosuvastatin Calcium 1 Pterocarpus marsupium 1 Progesterone 1 Pharmacogenomic Variants 1 Metformin 1 Medroxyprogesterone Acetate 1 Levonorgestrel 1 Hysterectomy 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Everolimus 1 Curettage 1 Biopsy 1 3,5-dimethoxy-4'-hydroxystilbene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02397083 2026-02-13

LEVER

M.D. Anderson Cancer Center

Phase 2 Active not recruiting

Endometrial Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡